Director, Early-Stage BD & Strategic Evaluation

CSL; Waltham (MA); Hybrid; USD 231,000 - 299,000; Full time

Job summary

CSL Behring in Waltham, MA is seeking a Director, BD Early Stage to lead evaluation of early-stage external innovation opportunities from Due Diligence Stage 2 through negotiation of a Non-Binding Offer, integrating scientific advances, therapeutic trends and market dynamics to guide CSL's BD investment decisions.

The role provides leadership for investment-ready assessments, strategic recommendations and governance-ready outputs, partnering with R&D, Commercial, Regulatory, Finance and

Qualifications

• 5-10+ years in pharmaceutical/biotech with exposure to Search & Evaluation, early-stage BD, R&D strategy or new product planning
• Proven ability to assess scientific/commercial potential and influence governance decisions
• Demonstrated success evaluating external opportunities, leading negotiations and influencing cross-functional and senior-level decisions

Responsibilities

• Lead evaluation of early-stage external assets from Due Diligence Stage 2 through Governance to negotiation of NBO
• Develop investment-ready assessments and strategic recommendations for CSL senior leaders
• Collaborate with cross-functional partners across R&D, Commercial, Regulatory, Finance and Transactions to inform governance decisions

Skills

Scientific literacy

Analytical thinking

External engagement

Executive communication

Cross-functional collaboration

Education

Bachelor’s degree in Life Sciences, Medicine, Pharmacy, Biology, Physiology or related (required)

Advanced degree such as PhD, MD, PharmD, MSc, MBA or equivalent (preferred)

Job description

CSL Behring in Waltham, MA is seeking a Director, BD Early Stage to lead evaluation of early-stage external innovation opportunities from Due Diligence Stage 2 through negotiation of a Non-Binding Offer, integrating scientific advances, therapeutic trends and market dynamics to guide CSL's BD investment decisions.

The role provides leadership for investment-ready assessments, strategic recommendations and governance-ready outputs, partnering with R&D, Commercial, Regulatory, Finance and